Feature|Videos|April 6, 2026

Reducing Risk in Small Molecule Development: Choosing the Right CDMO Partner

Key Takeaways

  • Understand the most common challenges pharmaceutical and biotech companies face when selecting a CDMO partner for small molecule development and manufacturing.
  • Learn which technical, operational, and regulatory capabilities are most important when evaluating CDMO partners.
SHOW MORE

Terry Novak, CEO of Benuvia, explores how pharmaceutical and biotech companies can mitigate development risks and accelerate speed-to-market by prioritizing technical alignment, robust project management, and early-stage collaboration with the right CDMO partner.

Terry Novak from Benuvia reviews the key strategies for reducing risk in small molecule development by prioritizing technical alignment and robust project management when selecting a contract development and manufacturing organization (CDMO). He explains how early collaboration is critical to accelerating timelines and ensuring a seamless transition from development to large-scale GMP manufacturing. He also covers emerging industry trends, including the strategic move toward reshoring and the increased demand for specialized expertise in niche markets.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.